Presented on July 19, 2024.
Juvena Therapeutics presents on their myotonic dystrophy program, focusing on JUV-161, a therapeutic protein that has demonstrated the ability to restore muscle differentiation, promote survival, increase strength, and improve metabolism by restoring protein signaling mechanisms that are crucial for muscular and metabolic homeostasis. Click here to learn more about Juvena Therapeutics.
Presenters include:
- Hanadie Yousef, PhD, Chief Executive Officer & Co-Founder, Juvena Therapeutics
- Jeremy O’Connell, PhD, Chief Scientific Officer & Co-Founder, Juvena Therapeutics
- Bernard (Barney) King, MD, MBA, Chief Medical Officer, Juvena Therapeutics
- John Day, MD, PhD, Scientific & Clinical Advisor, Juvena Therapeutics; and Professor of Neurology, Pediatrics (Genetics) and Pathology, Director of the Division of Neuromuscular Medicine at Stanford University
MDF Resources referenced in the Video:
- Toolkits & Publications
- MDF Support Groups
- Digital Academy
- Calendar of Events
- DM Drug Development Pipeline
- Myotonic Dystrophy Family Registry (MDFR)
- 2025 MDF Annual Conference
- Sign up for My Dispatch, our monthly e-newsletter
About Meet the Myotonic Dystrophy Drug Developers
Biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates!
